Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Ariad Stock's Biggest Risk Is Its Only Hope

Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals (NASDAQ: ARIA  ) an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion.

After a dramatic FDA recall in 2013 based on a handful of serious adverse events and patient deaths related to an Iclusig clinical trial, it appears that the drug is back on the market – but with a very tarnished reputation in the medical community that could prevent it from ever becoming a blockbuster.

As Ariad attempts to bring Iclusig into new cancer indications, investors are attempting to weigh the potential benefits of this drug against the possibility of failure in clinical trials –whether its due to adverse events and patient deaths or lack of efficacy against cancer.

Iclusig's current commercial prospects are dim
There are roughly 3,000-5,000 people who develop Chronic Myeloid Leukemia (CML) each year in the United States. At a price of $115,000 per patient, this means that Iclusig could have anywhere between $345-575 million in maximum potential revenues from the CML indication alone.

These figures sound good on paper, but the reality is that Iclusig will only be able to capture a small fraction of this patient population given its current status as a "drug of last resort" for patients with CML or Ph+ ALL.

Although Iclusig succeeded in proving its patient response benefit during its phase 3 development, its lack of proven survival benefit in CML patients – and its ominous black box warning – will continue to deter its use.

Other tyrosine kinase inhibitors (TKIs), like Gleevec (imatinib), will also threaten Iclusig directly in the CML indication with a superior reputation and cheaper pricing. And because there are only a few CML patients who cannot be prescribed competing TKIs, Iclusig is a last-ditch option for just a few select patients who could end up choosing palliative care instead.

It's hard to say how many total patients Iclusig could realistically target given its current prescription label, but based on recent sales figures it seems that the drug will only be used in a few hundred US patients per year. This really isn't enough to justify the company's current valuation.

Can Iclusig expand its prospects?
Ariad was making an attempt to turn Iclusig into a first-line CML drug with the infamous phase 3 EPIC trial, which was terminated in 2013 due to patient deaths and severe adverse events related to administration of Iclusig.

Because this was the trial that was supposed to make Iclusig into a blockbuster, it was a huge blow to investor morale when the trial (which was representative of Iclusig's chances in CML) fell apart last year.

But as discouraging as it may have been, Ariad management is still keen on turning Iclusig into a viable option in other indications.

Knowing that its opportunities in CML are limited, Ariad is now developing Iclusig/ponatinib in a number of alternative oncology indications, including gastrointestinal stromal tumors, lung cancer, acute myeloid leukemia (AML) and medullary thyroid cancer (MTC). These programs are all in phase 2, and it's impossible to say whether or not they succeed given what little we know right now.

What we do know is that future trials for these alternative programs will hit Ariad's bottom line pretty hard throughout the next few years, since thousands of patients will have to be enrolled into upcoming phase 2/3 trials.

This aggressive effort to expand Iclusig/ponatinib increases the risk of Ariad as an investment, but it is necessary to give Ariad a chance at recovering lost ground.

What could go wrong? Plenty.
If Ariad continued to see high rates of Iclusig-induced serious adverse events and/or deaths among cancer patients in its new trials, the stock could be in serious trouble. Even if the FDA allowed Iclusig to stay on the market as a third-line CML drug with its current black box warning, we know that the company' wouldn't be able to generate enough money to sustain a financial valuation anywhere near $1 billion.

So basically, Iclusig needs to be developed for a myriad of new indications while simultaneously fixing its reputation as a dangerous drug. That won't be easy, and there is simply too much that could go wrong -- I'd prefer to stay away.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (6) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 16, 2014, at 1:53 PM, biotechnique wrote:


    what was Gleevec's MMR after 9 months vs ICLUSIG? Iclusig 86% and where did gleevec end up? Barely 30%. Ask Abdul Kareem Jabar how well he did on molecular response. Even a Novartis study shows the deep major molecular response is the only thing that provides long term survival....Gleevec should be removed from the market...due to similar SAE's as ICLUSIG, but what's worst....very few respond to Gleevec when compared to ICLUSIG. If I had CML I would go with ICLUSIG first for the deep response and then reduce dosage to avoid the SAE's....simple...and if you knew what you'were talking about Wilson the info I posted would be in your are just a tool....a little short tool.

  • Report this Comment On July 17, 2014, at 9:50 AM, BiotechWilson wrote:

    Not only does Gleevec not have a black box warning, but it has proven OS benefit in other cancers. Doctors will continue to use this TKI first, until another CML trial is run

    Do you not agree the Ariad needs to expand Iclusig into AML, GIST, Lung, etc. ?

  • Report this Comment On July 17, 2014, at 12:13 PM, honghaodo wrote:

    Hi Brian Wilson. Because of your article, ARIADs stock has fallen over 15% within 3 days. Are you now happy yet?

  • Report this Comment On July 18, 2014, at 8:28 AM, biotechnique wrote:

    Hey Wilson, The EPIC trial results from ASCO comparing ICLUSIG against Gleevec, show that Gleevec can only achieve a MMR in 30% of the ptms, while ICLUSIG achieve 90%!!

    Also, Gleevec-Teva generic is coming. This may allow that TKI remain in 1st line for now, because of cost, but not because of efficacy. ICLUSIG, even with it's current black box, will eventually pick-up all the fall out from Gleevec and second line TKI's, everyone fails Gleevec over time.

    Also, if u have done any DD on ICLUSIG , which sounds like you haven't, they're in clinical trials for all the small indications of Gleevec and more! Gist, thyroid cancer, lung cancer etc... again ICLUSIG is cleaning up after gleevec's fallout in gist.

    This is why if I had CML,I would demand the TKI that has the greatest efficacy and blocks all known mutants!! And that TKI is ICLUSIG!! The black box was created by the FDA....based on the PACE trial....which included side effects from all of the other existing TKI's. The SAE's seen with ICLUSIG can be managed, as shown by Dr. Cortes study on dosing....

  • Report this Comment On July 23, 2014, at 10:31 AM, BioBat wrote:

    A couple points worth refuting. While there are only 4500-5000 new cases of CML every year, the total number of patients living with CML in any given year in the US is 70000. Gleevec will most certainly be the first line therapy for the foreseeable future but when resistance arises (it often does), gleevec offers no hope and a black box warning isn't going to deter doctors from prescribing and patients from taking iclusig because the fact is, it works.

    This will be a blockbuster drug within 5 years.

  • Report this Comment On August 20, 2014, at 10:49 AM, OriginalNewman1 wrote:

    Why are they posting this information now???

    This article was posted a month ago.

    Just goes to show you who are the ones that didn't get in and want another chance to drive the price lower.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3030276, ~/Articles/ArticleHandler.aspx, 8/28/2015 1:44:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Wilson

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:00 PM
ARIA $6.98 Up +0.29 +4.33%
Ariad Pharmaceutic… CAPS Rating: ***